Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) Management in a Spanish University Hospital Abstract #641

Introduction: GEP-NETs are malignant entities poorly understood still, deserving important attention for a better management of the disease.
Aim(s): To describe the clinical features and management of metastatic GEP-NETs patients in a reference oncology university hospital.
Materials and methods: Retrospective study including patients with GEP-NETs from the daily clinical practice in 2009. Data was provided from the Pathology Department, achieving positivity for chromogranin A (CGA) 75%, synaptophysin 96% and enolase 48%.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Msc MD María Del Pilar Solis-Hernandez

To read results and conclusion, please login ...

Further abstracts you may be interested in

#639 Clinical Features and Treatment of GEP NETs in a Spanish Hospital Through 8 Years
Introduction: There are discrepancies in Gastroenteropancreatic NETs (GEPNET) incidence, characteristics and patterns of care among institutional registries and countries.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Msc MD María del Pilar Solis
#895 Determination of a Prognostic Classification System in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (PNETs)
Introduction: There is no clinical prognostic risk stratification tool available for metastatic grade 1 and 2 PNETs, which are a heterogeneous group.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: MD Julen Fernández Plana
#938 Clinical Characteristics of 144 patients (pts) Included in a Multidisciplinary Group, with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) G2 (WHO 2010). Grupo Argentum.
Introduction: Neuroendocrine tumors (NETs) G2 of the digestive tract are a heterogeneous group of tumors. Several treatment options including chemotherapy and target therapy are used, but there is a lack of prospective trials assessing the role of predictive factors in this population.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Juan Manuel O'Connor
#943 SSA Therapy for Patients with Bronchial Carcinoids (BC) in the Community Setting
Introduction: SSA show antitumoral effect in GEP-NETs in 2 phase III trials, PROMID and CLARINET. However, patients (pts) with BC were not included in these studies.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Carlos Lopez Lopez
Keywords: bronchial, carcinoid, SSA
#1252 Radio-chemotherapy versus Surgery in Non-metastatic Ano-rectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues
Introduction: Neuroendocrine carcinomas (NEC) of the anus or the rectum are a rare disease, accounting for less than 1% of all digestive malignancies. Most are metastatic at diagnosis and treated with a platinum-based chemotherapy. No guidelines for localized tumors exist.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Bertrand Brieau